MARSHALL WACE, LLP
Q2 2020 13F-HR Holdings
Net value change ($000)
+4,261,911
(42.6%)
New positions
547
Sold out positions
665
Turnover %
29.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q1 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| TMUS | 151,557 | 3712.8% |
| TFX | 124,693 | 101.9% |
| PG | 122,164 | 720.0% |
| MSFT | 115,583 | 219.0% |
| Biohaven Pharmaceutical Holding Co Ltd. | 95,646 | 109.6% |
| UBS GROUP AG | 89,622 | 607.3% |
| ZTS | 88,538 | 44.0% |
| BABA | 83,498 | 42.3% |
| ABBV | 82,015 | 184.0% |
| GH | 75,493 | 158.4% |
Top Reduces (Value $000, Stocks/ETFs)
| Allergan plc | -177,100 | -100.0% |
| PYPL | -119,293 | -71.3% |
| MELLANOX TECHNOLOGIES LTD | -117,120 | -87.1% |
| LIN | -75,753 | -70.7% |
| RACE | -71,748 | -49.7% |
| JNJ | -70,454 | -72.0% |
| CYPRESS SEMICONDUCTOR CORP /DE/ | -68,217 | -100.0% |
| V | -65,870 | -68.8% |
| CI | -64,727 | -90.0% |
| NVDA | -62,713 | -92.5% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,475,147
(10.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|